Preclinical data published in Cell show the company’s COVID-19 vaccine candidate induces high neutralizing antibody titers after a single...
Developing Innovative
Best-in-Class Vaccines
Developing
Innovative
Best-in-Class
Vaccines
Computationally Designed VLP Vaccines
By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.
RSV and Covid-19 Vaccines
Our vaccine candidates for respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, have the potential to induce high neutralizing antibody titers for more effective protection.
In the News
BioSpace reporter Gail Dutton reports on Icosavax's computationally designed virus-like particle (VLP) vaccine platform as a potential fi...
For Nature Biotechnology's annual survey, the list of companies represents some of the best science that was spun out from academic insti...